Cowen & Co. Reaffirms Their Buy Rating on Ovid Therapeutics Inc

By Jason Carr

Cowen & Co. analyst Eric Schmidt maintained a Buy rating on Ovid Therapeutics Inc (NASDAQ: OVID) yesterday. The company’s shares closed on Thursday at $7.07.

According to TipRanks.com, Schmidt is a top 25 analyst with an average return of 42.6% and a 60.2% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Alexion Pharmaceuticals, and Akcea Therapeutics Inc.

Ovid Therapeutics Inc has an analyst consensus of Moderate Buy.

The company has a one-year high of $15.93 and a one-year low of $5.28. Currently, Ovid Therapeutics Inc has an average volume of 101.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ovid Therapeutics, Inc. is a biopharmaceutical company, which focuses on developing impactful medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.